Lyka Labs Limited (LYKALABS) announced its unaudited financial results for the second quarter and half year ended 30th September 2026 of the financial year 2026-27. The company reported significant growth across key financial metrics.

Revenue Growth

Standalone revenue from operations increased by 34.06% to Rs. 4,419.95 Lacs in Q2FY27 compared to Rs. 3,666.05 Lacs in the same period last year. Consolidated revenue from operations also rose by 20.56% to Rs. 4,419.95 Lacs.

EBITDA Margin Improvement

The standalone EBITDA margin improved significantly to 9.49% in Q2FY27 from (5.63)% in Q2FY26. Similarly, the consolidated EBITDA margin increased to 9.37% in Q2FY27 from (3.95)% in Q2FY26.

Profit Surge

Standalone net profit surged by 136.32% to Rs. 131.50 Lacs in Q2FY27, compared to a loss of Rs. 362.07 Lacs in Q2FY26. Consolidated net profit also showed a remarkable increase, rising by 139.54% to Rs. 127.11 Lacs in Q2FY27 from a loss of Rs. 321.44 Lacs in Q2FY26.

As a result, Lyka Labs Limited continues to demonstrate strong financial health and operational efficiency, setting a positive tone for the remainder of the financial year.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Lyka Labs Limited

Lyka Labs Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Lyka gains 25.2% over three months and trades near its 52-week highs. Thin margins at 6.6% leave limited room for error — any demand softness or cost spike hits the bottom line hard. No meaningful dividend — total return is entirely dependent on capital appreciation. Buyers show up with 2.1x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 25.2% in three months. Yet revenue grows at only 13.3% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Lyka Labs Limited.

OneSource Specialty Pharma Limited (NSE: ONESOURCE) announced today that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Sterile Product Division (SPD) facility in Bengaluru, with a ‘Voluntary Action Indicated’ (VAI) classification. This follows an inspection conducted from June 22 to June 30, 2026. This development highlights the company’s commitment to maintaining high standards of quality, regulatory compliance, and operational excellence.

Regulatory Milestone

The EIR with VAI classification signifies a regulatory milestone for OneSource. Neeraj Sharma, Managing Director & CEO, commented, “We are pleased to receive the EIR with VAI classification from the USFDA for our SPD facility. This outcome reflects our continued dedication to quality and compliance across our operations.”

Strategic Importance

The SPD facility plays a crucial role in OneSource’s sterile manufacturing capabilities, enabling the company to support the evolving needs of its global partners. This achievement adds to OneSource’s robust regulatory track record as it continues to build a globally competitive CDMO platform.

Future Outlook

As OneSource advances its capabilities in drug-device combinations, biologics, sterile injectables, and soft gelatin capsules, this milestone positions the company for continued growth and success in the pharmaceutical manufacturing sector. The company remains focused on delivering efficient, end-to-end solutions to its global clientele.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Onesource falls 14.8% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. No meaningful dividend — total return is entirely dependent on capital appreciation. RSI stands at 30, well into oversold territory. Yet sellers still dominated on 17 of recent sessions versus 13 for buyers, so the pressure has not fully lifted. Revenue grows at 232.4% yet the PEG reaches 99.00 — expensive for that growth. Furthermore, the stock drops 14.8% in three months. Neither value nor momentum supports this setup. It needs an earnings beat or a price reset first. Check Fundamentals of Onesource Specialty Pharma Limited.

Biocon Limited (NSE: BIOCON), an innovation-led global biopharmaceutical company, announced on October 29, 2026, that it has been ranked No. 13 among the Top 20 Global Employers in biotechnology, biopharmaceutical, pharmaceutical, and related industries in the 2026 survey conducted by the prestigious U.S.-based Science magazine. This recognition reflects Biocon’s long-standing reputation as an employer of choice in the global life sciences industry.

Recognition for Social Responsibility

Biocon was recognized for three key attributes: social responsibility, respect for employees, and a culture aligned with employee values. Shreehas Tambe, CEO and Managing Director, Biocon, said: “I am proud that Biocon has been recognized by Science magazine as one of the world’s Top 20 biopharmaceutical employers for the 15th consecutive year. This recognition reflects the talent, passion, and commitment of our people.”

People-Centric Culture

Biocon’s people-centric culture continues to be a key differentiator in strengthening its employer brand globally. Today, employees representing 37 nationalities across more than 60 cities worldwide contribute diverse perspectives and expertise to Biocon’s mission of delivering life-changing medicines to patients around the world.

As Biocon advances its ambition to become a fully integrated global medicines company, it remains committed to fostering a culture of innovation, excellence, and collaboration enabling it to make a meaningful difference to patients worldwide.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon drops 20.1% over three months and trades near its 52-week lows. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.